Amneal Pharmaceuticals Raises 2026 Guidance After Q3 Revenue Climbs 10% to $862.7 Million
Amneal Pharmaceuticals (AMRX) reported Q3 revenue of $862.7M, up 10% YoY, and adjusted EPS of $0.26, exceeding estimates. Adjusted EBITDA rose 30% to $207M. The company raised its 2026 revenue guidance to $3.15B-$3.25B and adjusted EPS guidance to $1.04-$1.08. Growth was driven by biosimilars, women's health, and specialty medicines.
How this was made
The 30-second read
Why it matters
The company’s Q3 results beat consensus on both revenue and adjusted EPS, and management raised full-year 2026 revenue and adjusted EPS guidance, creating a clear catalyst for earnings estimate revisions.
Market read
Traders can update positioning based on the newly raised 2026 guidance ranges and the Q3 beat, while monitoring the GAAP versus adjusted earnings gap.
What to watch
Investors may focus on whether Affordable Medicines and Specialty growth can sustain through Q4, since the guidance increase is explicitly tied to expected contributions for the remainder of 2026.
Background
Amneal is a US pharmaceutical company spanning biosimilars, specialty branded medicines, and affordable medicines.
Ticker impact
Amneal reported Q3 revenue up 10% to $862.7M and raised full-year 2026 revenue to $3.15B-$3.25B and adjusted EPS to $1.04-$1.08.
Likely upward pressure as the market prices in higher 2026 revenue and adjusted EPS, while investors weigh the persistent GAAP loss.
The article discloses both the Q3 beat (revenue and adjusted EPS) and explicit upward guidance ranges, which are direct inputs to near-term valuation and analyst model updates.
Market effects
Positive read-through for biosimilars and specialty pharma demand expectations, reinforcing the group’s earnings durability narrative.
Primarily US-listed large-cap pharma sentiment; limited direct regional spillover beyond healthcare equities.
Modest global relevance, as the catalyst is company-specific guidance rather than a cross-border policy or supply shock.
Counterpoint
The GAAP net loss of $22.0M highlights that adjusted profitability may not translate cleanly to GAAP earnings, limiting how far the stock can rerate.
Key entities
- companyAmneal Pharmaceuticals Inc.
Reported Q3 results and raised 2026 revenue and adjusted EPS guidance.
- executivesChirag Patel and Chintu Patel
Co-CEOs who attributed the guidance increase to strong broad-based performance.
